Bcl-2 anticorps (AA 41-54)

N° du produit ABIN967321

Détail du produit anti-Bcl-2 anticorps

Antigène: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Épitope: AA 41-54

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Bcl-2 est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Marque: BD Pharmingen™

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Human Bcl-2 synthetic peptide aa. 41-54

Isotype: IgG1

Information d'application

Indications d'application: Western Blot: Jurkat control lysate [50 µg (1 µg/µl)] is provided as a western blot positive control (Store lysate at -20° C). Additional control lysate (ABIN968537) is sold separately.
IHC: For paraffin-embedded sections, tissues should be fixed in either Bouin's fixative or formalin. For immunofluorescent staining and flow cytometry, our directly conjugated formats are recommended.

Commentaires:

Related Products: ABIN968537

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store undiluted at -20°C.

Références pour anticorps anti-Bcl-2 (ABIN967321)

Krajewski, Tanaka, Takayama, Schibler, Fenton, Reed: "Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes." dans: Cancer research, Vol. 53, Issue 19, pp. 4701-14, (1993) (PubMed).

Pezzella, Turley, Kuzu, Tungekar, Dunnill, Pierce, Harris, Gatter, Mason: "bcl-2 protein in non-small-cell lung carcinoma." dans: The New England journal of medicine, Vol. 329, Issue 10, pp. 690-4, (1993) (PubMed).

Tanaka, Saito, Reed: "Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival." dans: The Journal of biological chemistry, Vol. 268, Issue 15, pp. 10920-6, (1993) (PubMed).

Pezzella, Jones, Ralfkiaer, Ersbøll, Gatter, Mason: "Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma." dans: British journal of cancer, Vol. 65, Issue 1, pp. 87-9, (1992) (PubMed).

Reed, Meister, Tanaka, Cuddy, Yum, Geyer, Pleasure: "Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin." dans: Cancer research, Vol. 51, Issue 24, pp. 6529-38, (1992) (PubMed).

Williams: "Programmed cell death: apoptosis and oncogenesis." dans: Cell, Vol. 65, Issue 7, pp. 1097-8, (1991) (PubMed).

Pezzella, Tse, Cordell, Pulford, Gatter, Mason: "Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation." dans: The American journal of pathology, Vol. 137, Issue 2, pp. 225-32, (1990) (PubMed).

Détails sur Bcl-2

Antigène: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Autre désignation: Bcl-2 (BCL2 Produits)

Synonymes: anticorps Bcl-2, anticorps PPP1R50, anticorps bcl-2, anticorps AW986256, anticorps C430015F12Rik, anticorps D630044D05Rik, anticorps D830018M01Rik, anticorps BCL-2, anticorps Bcl2, anticorps BCL2, apoptosis regulator, anticorps B cell leukemia/lymphoma 2, anticorps B-cell CLL/lymphoma 2a, anticorps B-cell CLL/lymphoma 2 protein, anticorps BCL2, anticorps Bcl2, anticorps bcl2a, anticorps BCL-2

Sujet: Bcl-2 is considered to be novel among proto-oncogenes because it blocks apoptosis (programmed cell death) in many cell types. Apoptosis is an active form of cellular suicide that typically requires new RNA and protein synthesis and is associated with distinct morphological changes including cell shrinkage, cytoplasm membrane blebbing, nuclear fragmentation and DNA degradation. Because Bcl-2 blocks apoptosis it may contribute to tumorigenisis by prolonging cell survival, rather than by accelerating the rate of cell proliferation. Human Bcl-2 protein migrates at a molecular weight of ~26 kDa by SDS-PAGE. Bcl-2/100 recognizes a 26 kDa band representing human Bcl-2. Additional minor bands at 27-31 kDa and 18-21 kDa may also be visualized. The 27-31 kDa upper band may represent a larger isoform, whereas the 18-21 kDa lower band may be an internal translation or proteolytic product, therefore, a synthetic peptide corresponding to amino acids 41-54 (GAAPAPGIFSSQPG) of human Bcl-2 was used as immunogen. This peptide sequence is not conserved between human and mouse. Bcl-2/100 does not cross-react with mouse Bcl-2. For detection of mouse Bcl-2 refer to clone 3F11 (ABIN967441), polyclonal rabbit anti-rat/mouse Bcl-2 antiserum, and polyclonal rabbit anti-mouse Bcl-2 antiserum.

Pathways: Signalisation MAPK, Signalisation PI3K-Akt, Apoptose, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling